Nurtec ODT (Rimegepant) for Women 65 and Older: What You Need to Know About Transitioning Your Migraine Care

Why Migraine in Women Over 65 Deserves Its Own Conversation

Migraine does not simply stop at menopause. Roughly 10 percent of women over 60 still experience active migraine, and a subset enters their seventh decade still carrying a diagnosis that began in their teens or twenties. The picture shifts, though. Estrogen withdrawal during perimenopause often worsens attack frequency, and the post-menopausal years can bring either relief or a stubborn persistence of attacks that now travel with a longer list of comorbidities.

If you are a woman moving from your late fifties into your sixties, or already well past that marker, transitioning your migraine management is not just about swapping one drug for another. It means rethinking every tool in your regimen because your liver processes drugs more slowly, your kidneys clear them at a lower rate, your cardiovascular risk profile has changed, and triptans, which many women used for decades, carry warnings that become harder to justify after 65.

Rimegepant occupies a specific and useful role here. It does not constrict blood vessels the way triptans do. That single pharmacological fact opens a door for women who have accumulated cardiovascular risk factors in the decades since their first migraine prescription.

How the Post-Menopausal Hormonal Shift Changes Migraine

During reproductive years, migraine attacks in women are tightly linked to the estrogen drop in the late luteal phase. Menstrual migraine affects up to 60 percent of women with migraine, making hormonal cycling a central driver of attack timing.

After menopause, that cyclical trigger disappears. Attacks that remain tend to be less predictable in their timing and sometimes change in character. Some women find their aura frequency increases post-menopause. Others notice that attacks respond differently to the same acute medications they relied on for years, a shift that may reflect altered CGRP signaling in the context of sustained low estrogen.

Why Triptans Become Complicated After 65

Triptans work through 5-HT1B/1D receptor agonism that causes vasoconstriction. The FDA label for most triptans cautions against use in women with known cardiovascular disease, uncontrolled hypertension, or a history of stroke. The American Headache Society notes that the absolute cardiovascular risk from triptans in the general migraine population is low, but that risk-benefit calculus changes in older patients with accumulated comorbidities.

Ergotamines carry similar vascular concerns with an even narrower safety window. NSAIDs, used for decades, become riskier with age because of gastrointestinal bleeding, renal toxicity, and fluid retention affecting blood pressure control.

Rimegepant sidesteps the vasoconstrictive mechanism entirely.

What Rimegepant Is and How It Works

Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is released during migraine attacks and causes vasodilation and neurogenic inflammation in the trigeminovascular system. Rather than reversing that vasodilation through constriction (the triptan approach), rimegepant blocks the receptor so CGRP cannot bind.

The key BHV3000-305 trial showed rimegepant 75 mg achieved pain freedom at two hours in 19.6 percent of patients versus 12.0 percent with placebo (p<0.0001). That trial enrolled adults 18 and older. Women made up approximately 85 percent of the trial population, consistent with migraine's sex distribution, but the trial was not powered to detect differential effects by menopausal status.

This is where an honest evidence gap must be named: no published trial has enrolled a geriatric-specific or post-menopausal-specific cohort for rimegepant. The FDA label states that no clinically meaningful pharmacokinetic differences were observed in patients 65 and older compared to younger adults in population pharmacokinetic analyses, but the number of participants over 65 in those analyses was small. What we know about rimegepant in older women is largely extrapolated from general adult data, not directly studied in a dedicated geriatric cohort.

The 75 mg Orally Disintegrating Tablet

The tablet dissolves on the tongue without water. That formulation matters for older women who may have dysphagia or who take multiple pills and find swallowing one fewer tablet easier to manage. It reaches maximum plasma concentration in approximately 1.5 hours after oral administration. Bioavailability is approximately 64 percent, and the drug is primarily metabolized by CYP3A4 with minor contributions from CYP2C9.

Half-life is approximately 11 hours. The drug is not renally cleared to a significant degree, which is one reason the FDA requires no renal dose adjustment unless eGFR falls below 30 mL/min.

Dosing for Women 65 and Older

The approved dose is 75 mg as needed, no more than once every 48 hours for acute treatment. The same 75 mg tablet taken every other day serves as preventive therapy. FDA labeling does not recommend a reduced geriatric dose, based on population pharmacokinetic data showing age alone did not produce clinically meaningful exposure differences.

What Does Change With Age

Even without a labeled dose reduction, several physiological changes in older women affect how rimegepant behaves in practice.

Slower hepatic metabolism. Liver blood flow and microsomal enzyme activity decline with age. CYP3A4 activity, the primary pathway for rimegepant metabolism, may be reduced. The practical implication is that older women on strong CYP3A4 inhibitors, such as clarithromycin, certain antifungals like ketoconazole, or some HIV protease inhibitors, will experience meaningfully higher rimegepant plasma levels. The label advises avoiding concomitant use of strong CYP3A4 inhibitors, and that caution applies more acutely when hepatic reserve is already diminished by age.

Lower baseline albumin. Rimegepant is approximately 96 percent protein-bound. Older women often have lower serum albumin. Lower protein binding means a higher free drug fraction, which could amplify both effect and any adverse effects. This is not accounted for by a blanket dose reduction in the label, but it is worth discussing with your prescriber if you have known hypoalbuminemia.

Polypharmacy. The average woman over 65 takes five or more prescription medications. Drug-drug interactions are the mechanism behind approximately 20 to 30 percent of adverse drug events in older adults. Running a full medication reconciliation before starting rimegepant is not optional in this age group.

Renal Function and Dose

No dose adjustment is required for mild to moderate renal impairment. For severe impairment defined as eGFR <30 mL/min, the label recommends avoiding rimegepant. Women with diabetic nephropathy, long-standing hypertension, or recurrent UTI history should have a current eGFR on file before starting.

Hepatic Function and Dose

Avoid rimegepant in severe hepatic impairment (Child-Pugh C). Mild to moderate hepatic impairment does not require dose adjustment per current labeling.

Drug Interactions That Matter Most for Older Women

Rimegepant's metabolism through CYP3A4 and its role as a P-glycoprotein (P-gp) substrate create several clinically important interactions that older women are disproportionately likely to encounter.

Cardiovascular Medications

Many women over 65 take calcium channel blockers such as diltiazem or verapamil for hypertension or atrial fibrillation. Both are moderate CYP3A4 inhibitors. Combined use with rimegepant may increase rimegepant exposure by roughly twofold. The label recommends a maximum of one dose in 48 hours when using moderate CYP3A4 inhibitors, which is already the standard dose interval, so in practice the clinical concern is more about monitoring for side effects like nausea than adjusting timing.

Antidepressants and Hormone Interactions

SSRIs and SNRIs, commonly prescribed in post-menopausal women for mood symptoms and vasomotor symptom management, are generally not significant CYP3A4 inhibitors. Serotonin syndrome risk with rimegepant is not a labeled concern in the way it is with triptans.

Hormone therapy (HT) for menopausal symptoms does not appear to interact with rimegepant through a named pharmacokinetic mechanism, but if you use transdermal estradiol or combined HT and your migraine pattern changes after starting rimegepant, document the timeline and report it to your prescriber.

Osteoporosis Medications

Bisphosphonates are primarily renally cleared and do not interact with rimegepant's CYP pathway. Denosumab and other biologics used for osteoporosis similarly do not share a metabolic route. This is reassuring given how common osteoporosis treatment is in this age group.

Pregnancy, Lactation, and Contraception

This section is required for every drug article on WomanRx, and it applies to women 65 and older in a specific, often overlooked way.

Pregnancy

Rimegepant is contraindicated in pregnancy. Animal reproduction studies showed adverse developmental outcomes at clinically relevant exposures. There are no adequate human pregnancy data. While natural pregnancy after age 65 is exceptionally rare, women who have used donor egg technology or who are in perimenopause transitioning into this age group must be aware of this contraindication.

If you are in your early sixties and not yet confirmed as post-menopausal (defined as 12 consecutive months without a menstrual period), discuss whether contraception is still indicated before starting rimegepant.

Lactation

It is not known whether rimegepant transfers into human breast milk. Animal data showed presence in milk at concentrations higher than maternal plasma. The FDA label advises that the developmental and health benefits of breastfeeding should be weighed against the mother's need for rimegepant and any potential adverse effects on the infant.

For most women over 65, lactation is not an active consideration. For women in their early sixties who are caring for grandchildren or who entered this age group after late-life parenthood through assisted reproduction, the question is not irrelevant.

Contraception

No specific contraceptive requirement is embedded in the rimegepant label in the way it is for known teratogens such as valproate or thalidomide. For women who are not confirmed post-menopausal and who are sexually active with any pregnancy potential, the general principle of avoiding rimegepant in pregnancy should guide the conversation with your clinician.

Who This Is Right For (and Who Should Pause)

Women Over 65 Who May Benefit Most

You are a strong candidate to discuss rimegepant if you are a woman over 65 who:

• Has established migraine with or without aura that has persisted into post-menopause
• Previously used triptans effectively but now has cardiovascular contraindications including coronary artery disease, uncontrolled hypertension, or a history of stroke or TIA
• Experiences frequent attacks (four or more per month) and wants a single drug that can serve both acute and preventive functions
• Has gastrointestinal sensitivity that limits NSAID use
• Experiences nausea during attacks and benefits from a tablet that dissolves without swallowing

Women Who Should Approach With More Caution

The drug may not be the right choice if you:

• Are taking a strong CYP3A4 inhibitor that cannot be substituted (the interaction is not safely manageable with dose timing alone)
• Have severe hepatic impairment (Child-Pugh C)
• Have an eGFR below 30 mL/min
• Have an active liver disease with hepatocellular dysfunction beyond Child-Pugh B

The Cardiovascular Advantage in Post-Menopausal Women

Post-menopausal women face a substantially higher absolute cardiovascular risk than they did during their reproductive years. Cardiovascular disease is the leading cause of death in women over 65 in the United States. The absence of vasoconstrictive activity in rimegepant means it does not add to that risk in the way triptans do, making it one of the few migraine-specific treatments with a genuinely favorable cardiovascular profile in this population.

Transitioning Your Migraine Care: A Practical Framework

Transitioning from midlife migraine management to a geriatric care model is not a single appointment. It is a process, and rimegepant may occupy a different role in each phase.

Step 1: Audit Your Current Regimen

Before your transition visit, list every medication you take including supplements, because St. John's Wort is a strong CYP3A4 inducer that will reduce rimegepant plasma levels. Grapefruit and grapefruit juice inhibit CYP3A4 and can raise rimegepant exposure. Both are more common in daily routines than clinical notes often capture.

Step 2: Get Baseline Labs

Ask your clinician for a current eGFR, hepatic function panel, and serum albumin if not done in the past year. These values determine whether any of the caution thresholds apply to you.

Step 3: Define Your Migraine Goal

Some women over 65 want acute treatment only. Others have crossed the threshold for preventive therapy, generally defined as four or more migraine days per month, migraine that significantly impairs function even at lower frequency, or prior medication-overuse headache from frequent acute treatment. The American Headache Society defines this frequency threshold for preventive therapy at four or more migraine days per month with or without significant disability. Rimegepant is the only oral CGRP receptor antagonist approved for both indications in one formulation.

Step 4: Plan for the 48-Hour Rule

The every-other-day schedule for prevention and the once-per-48-hours limit for acute use require some planning. If you take a preventive dose on Monday and develop an acute attack on Tuesday, you cannot take a second dose until Wednesday. Build this into your tracking system, whether an app or a paper diary, before you start.

Step 5: Set a 3-Month Review Point

Unlike triptans, where you know within two hours whether the drug worked, rimegepant's preventive effect takes weeks to establish. Clinical trial data for the preventive indication showed that monthly migraine days began to separate from placebo by week four and continued improving through week 12. Set a calendar reminder for a three-month check-in with your prescriber to assess whether the preventive schedule is working.

Managing Side Effects in Older Women

The most common adverse effects reported in rimegepant trials are nausea (approximately 2 percent) and urinary tract infection (approximately 2 percent). Neither rate differed significantly from placebo in the BHV3000-305 trial.

For older women, the UTI signal is worth watching. Post-menopausal genitourinary changes increase baseline UTI risk, and rimegepant may not be causing UTIs so much as being used in a population where they occur. Report any new urinary symptoms to your provider and do not assume they are unrelated to your new medication.

Nausea from rimegepant may be easier to manage than nausea from oral medications during a migraine attack precisely because the orally disintegrating formulation bypasses the need for swallowing during gastric stasis.

Liver enzyme elevations have been reported rarely. Women with pre-existing hepatic conditions should have liver function monitored periodically, though no specific monitoring interval is specified in the label.

The Evidence Gap: What We Know and What We Don't

Women over 65 deserve honest information about what the data actually shows. Here it is, plainly stated.

The key efficacy trials for rimegepant enrolled predominantly younger adults. The BHV3000-305 trial had a mean participant age of approximately 41 years. The preventive trial published in Lancet enrolled a similarly young average population. Post-menopausal women were not studied as a distinct subgroup in either trial.

The pharmacokinetic population analysis supporting the "no dose adjustment needed" conclusion in older adults included a small number of participants over 65. The FDA's Prescribing Information does not quantify exactly how many, which limits confidence in the precision of that conclusion.

What this means for you: the absence of a required dose reduction is not the same as having strong geriatric-specific data. It means no age-based difference was detected in the available pharmacokinetic data, not that the drug has been thoroughly validated in women your age and life stage. Work with a clinician who understands both geriatric pharmacology and women's headache medicine, and report any unexpected responses, whether better or worse than expected, so real-world data in this population continues to grow.

A Note on Hormone Therapy and Migraine After 65

Some post-menopausal women begin or continue hormone therapy for vasomotor symptoms, GSM (genitourinary syndrome of menopause), or bone health. The Menopause Society (formerly NAMS) states that for appropriate candidates under age 60 or within 10 years of menopause onset, HT has a favorable benefit-risk profile. Women who start HT after 65 require more individualized risk discussion.

Estrogen-containing HT can affect migraine patterns. Some women experience more frequent attacks on oral estrogen due to fluctuating levels, while transdermal delivery maintains steadier levels and may be less provocative. If you are on HT and starting rimegepant, or on rimegepant and considering HT, document your migraine diary through the transition period. Neither drug interacts with the other pharmacokinetically, but the hormonal effect on migraine frequency could be mistaken for a rimegepant effect in either direction.

As WomanRx reviewer Dr. Rachel Goldberg notes: "The women I see who are over 65 with persistent migraine have often been undertreated for years because their physicians assumed migraine resolves at menopause or because they aged out of what their doctor considered standard migraine candidates. Rimegepant gives us a vasoconstrictive-agent-free option that fits the cardiovascular reality of post-menopausal women, and the dual acute-preventive approval simplifies a regimen that might otherwise require two separate drugs."